selected publications
-
Structures revealing mechanisms of resistance and collateral sensitivity of Plasmodium falciparum to proteasome inhibitors.
Nature communications.
2023
Academic Article
GET IT
Times cited: 17 -
Dual-pharmacophore artezomibs hijack the Plasmodium ubiquitin-proteasome system to kill malaria parasites while overcoming drug resistance.
Cell chemical biology.
2023
Academic Article
GET IT
Times cited: 13 -
Discovery of Highly Selective Inhibitors of the Human Constitutive Proteasome β5c Chymotryptic Subunit.
Journal of medicinal chemistry.
2023
Academic Article
GET IT
Times cited: 4 - Discovery of (S)-N-(2-Amino-4-fluorophenyl)-4-(1-(3-(4-((dimethylamino)methyl)phenyl)-6-oxopyridazin-1(6H)-yl)ethyl)benzamide as Potent Class I Selective HDAC Inhibitor for Oral Anticancer Drug Candidate. Journal of medicinal chemistry. 2023 Academic Article
-
Exploration of novel macrocyclic dipeptide N-benzyl amides as proteasome inhibitors.
European journal of medicinal chemistry.
2018
Academic Article
GET IT
Times cited: 4 -
Design, synthesis, and biological evaluation of novel phenol ether derivatives as non-covalent proteasome inhibitors.
European journal of medicinal chemistry.
2018
Academic Article
GET IT
Times cited: 7 -
Development of Macrocyclic Peptides Containing Epoxyketone with Oral Availability as Proteasome Inhibitors.
Journal of medicinal chemistry.
2018
Academic Article
GET IT
Times cited: 18 -
Integrating docking scores, interaction profiles and molecular descriptors to improve the accuracy of molecular docking: toward the discovery of novel Akt1 inhibitors.
European journal of medicinal chemistry.
2014
Academic Article
GET IT
Times cited: 53